1 第一拖拉機股份有限公司 2024 年度報告 重要提示 | 未出席董事職務 | 未出席董事姓名 | 未出席董事的原因說明 | 被委託人姓名 | | --- | --- | --- | --- | | 董事 | 方憲法 | 因公務 | 楊建輝 | 公司第九屆董事會第三十三次會議審議通過了公司2024年度利潤分配預案：以公司截止2024年12月31日 總股本1,123,645,275股為基數，向全體股東每10股派發現金紅利人民幣2.995元（含稅），共計派發現金紅利 33,653萬元，公司本年度不進行資本公積金轉增股本。 六、 前瞻性陳述的風險聲明 本報告涉及的本公司發展戰略、經營計劃等前瞻性陳述不構成本公司對投資者的實質承諾，敬請投資者注意 風險。 七、 是否存在被控股股東及其他關聯方非經營性佔用資金情況 否 十、 重大風險提示 本公司結合自身所處行業及經營運行情況，本着重要性原則，在本年度報告「管理層討論與分析」中對公司經 營與未來發展中可能面臨的風險進行了分析和闡述，敬請查閱。 一、 本公司董事會、監事會及董事、監事、高級管理人員保證年度報告內容的真實性、準確性、完整性，不存在虛 假記載、誤導性陳述或重大 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI ELECTRIC GROUP COMPANY LIMITED 上海電氣集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02727） 2025 年第一季度報告 根據中國證券監督管理委員會和上海證券交易所的相關法律法規，上海電氣集團股份有限 公司（「本公司」）須披露季報。 | | | 本報告期比上 | | --- | --- | --- | | 項目 本報告期 2 | 上年同期 | 年同期增減變 | | | | 動幅度(%) | 1 * 本公告是根據香港法例第 571 章證券及期貨條例第 XIVA 部項下內幕消息條文（定義見香 港聯合交易所有限公司證券上市規則（「上市規則」））及上市規則第 13.09(2)和第 13.10B 條 的要求發佈。 本公司董事會（「董事會」）謹此宣佈本公司及其附屬公司按照中國企業會計準則編制截至 2025 年 3 月 31 日止三個月的 ...

Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching RMB 1.2 billion in the last quarter[9]. - Revenue for the fiscal year ending December 31, 2024, increased by 17.1% to RMB 2,060.8 million from RMB 1,759.6 million in 2023[17]. - Profit for the fiscal year ending December 31, 2024, rose by 31.0% to RMB 428.3 million compared to RMB 327.0 million in 2023[17]. - Gross profit rose by 20.8% from RMB 658.1 million in 2023 to RMB 795.1 million in 2024, with gross margin improving from 37.4% to 38.6%[25]. - The company reported a net profit margin of 12%, reflecting improved operational efficiency compared to the previous year[9]. - Other income increased by 19.9% from RMB 48.2 million in 2023 to RMB 57.8 million in 2024, primarily due to increased government subsidies[26]. - Selling and distribution expenses grew by 25.9% from RMB 103.2 million in 2023 to RMB 129.8 million in 2024, driven by higher employee compensation and business development costs[27]. - Administrative expenses increased by 10.8% from RMB 175.0 million in 2023 to RMB 193.9 million in 2024, mainly due to a rise in R&D expenses[28]. - The company's distributable reserves as of December 31, 2024, are approximately RMB 1,159.0 million, an increase from RMB 968.3 million as of December 31, 2023[101]. User Growth and Market Expansion - User data showed a growth in active users by 25%, totaling 5 million users as of the end of the quarter[9]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[9]. - Marketing efforts will be intensified to expand the customer base in China, including participation in industry exhibitions and collaborations with optical service providers[20]. - The company aims to enhance its online marketing strategies through platforms like Douyin and WeChat mini-programs[20]. Future Outlook and Strategic Initiatives - The company provided a future outlook, projecting a revenue growth of 20% for the next fiscal year[9]. - New product launches included two innovative optical devices, expected to contribute an additional RMB 300 million in revenue[9]. - A strategic acquisition of a local competitor was announced, valued at RMB 500 million, aimed at enhancing market capabilities[9]. - The company plans to implement a new marketing strategy, aiming to increase brand awareness by 40% in the next year[9]. Research and Development - Research and development investment increased by 30%, totaling RMB 150 million, focusing on advanced optical technologies[9]. - The company is focusing on strengthening its R&D capabilities, including the establishment of a national-level R&D center for XR technology[18]. - Collaboration with leading global technology and consumer electronics companies will continue to advance existing R&D projects and explore new opportunities in AR and AI eyewear[21]. Corporate Governance and Board Structure - The company emphasizes the importance of independent opinions and judgments provided by its independent non-executive directors[66][67][69]. - The board of directors includes members with diverse backgrounds in finance, law, and medical fields, enhancing the company's strategic decision-making capabilities[66][70]. - The company is committed to maintaining high standards of corporate governance through the expertise of its board members[66][70]. - The re-election and appointment of directors reflect the company's ongoing efforts to strengthen its leadership team and governance structure[63][64][66][67][69][70]. Financial Position and Assets - Total assets increased to RMB 2,388.8 million by the end of 2024, up from RMB 1,984.3 million in 2023[13]. - Total assets increased by 20.4% from RMB 1,984.3 million in 2023 to RMB 2,388.8 million in 2024, while total liabilities rose by 36.3% from RMB 589.4 million to RMB 803.2 million[34]. - Cash and cash equivalents increased by 51.0% from RMB 330.5 million in 2023 to RMB 499.1 million in 2024, attributed to increased bank borrowings and higher cash generated from operations[35]. Employee and Compensation Matters - Employee benefit expenses, including salaries and other benefits, amounted to approximately RMB 430.8 million for the year ending December 31, 2024, compared to RMB 387.5 million for the previous year[50]. - The company has established a compensation committee to formulate and review the compensation policies for directors and senior management[123]. - The remuneration policy for directors and senior management includes basic salary, discretionary bonuses, and share rewards[193]. Environmental, Social, and Governance (ESG) Initiatives - The board emphasizes compliance with applicable Chinese laws and regulations, with no significant violations reported as of December 31, 2024[94]. - The company has established an Environmental, Social, and Governance (ESG) committee to oversee compliance with environmental laws and regulations[93]. - The ESG Committee's responsibilities include evaluating the company's performance and its environmental impact, as well as reviewing the draft of the annual ESG report[190]. Risk Management and Internal Controls - The company has implemented appropriate insurance arrangements for its directors and senior management to minimize risks associated with legal proceedings[168]. - The company has established a comprehensive internal control system that effectively mitigates risks and complies with legal requirements[147]. - The company will keep monitoring the effectiveness of its risk management and internal control systems[141]. Shareholder Matters - The proposed final dividend for the year ending December 31, 2024, is RMB 0.16 per share, a decrease from RMB 0.20 per share for the year ending December 31, 2023[46]. - The company has no predetermined dividend payout ratio, and future dividends will depend on operational performance, financial condition, and cash availability[90]. - The company has adopted a shareholder communication policy to ensure transparent and accurate communication with shareholders, which was reviewed and deemed effective during the reporting period[199].

Seacon Shipping Group Holdings Limited 洲際船務集團控股有限公司 （ 於開曼群島註冊成立的有限公司 ） 股份代號 : 2409 年報 目錄 | | | 2024年度報告 洲際船務集團控股有限公司 02 公司資料 郭金魁先生 （主席） 陳澤凱先生 （總裁） 賀罡先生 趙勇先生 獨立非執行董事 傅俊元先生 張雪梅女士 莊煒先生 審核委員會 執行董事 傅俊元先生 （主席） 張雪梅女士 莊煒先生 薪酬委員會 張雪梅女士 （主席） 陳澤凱先生 莊煒先生 提名委員會 郭金魁先生 （主席） 陳澤凱先生 傅俊元先生 張雪梅女士 莊煒先生 風險管理委員會 郭金魁先生 （主席） 賀罡先生 傅俊元先生 張雪梅女士 莊煒先生 環境、社會及管治委員會 郭金魁先生 （主席） 趙勇先生 莊煒先生 聯席公司秘書 孫玉峰女士 陳詩婷女士 (FCG, HKFCG) 授權代表 賀罡先生 陳詩婷女士 註冊辦事處 P.O. Box 31119 Grand Pavilion Hibiscus Way, 802 West Bay Road Grand Cayman KY1-1205 Cayman Islands 中國 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號：00270） 以實物分派粤海置地股份的方式支付特別股息已於 2025 年 1 月 21 日完成。 1 粤海投資有限公司 備註： 本公司將按香港《公司條例》 ( 第 622 章 ) 第 662(3) 條及附表 6 第 3 部的規定，將截至 2024 年 12 月 31 日止年度的綜合財務報表適時送呈公司註冊處處長。本公司的核數師已就該等綜合財務報表提交報 告。報告中核數師並無保留意見，亦無提述任何其在無提出保留意見下強調須予注意的事項，也沒 有任何根據香港《公司條例》 ( 第 622 章 ) 第 406(2) 、 407(2) 或 (3) 條的述明。 (3) 此公告為本公司自願性披露，以進一步提升本公司的企業管治水平及透明度。本公司將於往後的財 政年度繼續按季度公佈財務資料。 表現摘要 本集團於本期間的未經審核持續經營業務綜合收入為 46.17 億港元（2024 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 2025年第一季度報告 根 據 上 海 證 券 交 易 所 的 規 定，本 公 司 需 於 第 一 季 度 和 第 三 季 度 刊 發 季 度 報 告。 本季度報告內所載的財務數據均未經審計，並根據中國會計準則而編製。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.09條 及 13.10B條 與 及 證 券 及 期 貨 條 例（香 港 法 例 第571章）第XIVA部項下內幕 消 息 條 文 而 刊 發。 重要提示 – 1 – (1) 華能國際電力股份有限公司（「本公司」、「華能國際」）董 事 會、監 事 會 及 其 董 事、監 事、高 級 管 理 人 員 保 證 季 度 報 告 內 容 的 真 實、準 確、 完 整，不 存 在 虛 假 記 載、誤 導 性 陳 述 或 者 重 大 遺 漏，並 承 擔 個 別 及 連 帶 的 法 ...

| 財務摘要 | 02 | Financial Highlights | | --- | --- | --- | | 五年財務概要 | 03 | Five Year Financial Summary | | 主席報告 | 04 | Chairman's Statement | | 公司資料 | 09 | Corporate Information | | 董事及高級管理人員履歷 | 12 | Profile of Directors and Senior Management | | 管理層討論與分析 | 17 | Management Discussion and Analysis | | 企業管治報告 | 30 | Corporate Governance Report | | 董事會報告 | 52 | Directors' Report | | 獨立核數師報告 | 65 | Independent Auditor's Report | | 綜合損益及其他全面收益表 | 72 | Consolidated Statement of Profit or Loss and Other | | | | Com ...

Financial Performance - The company reported a revenue of HKD 1.2 billion for the fiscal year 2024, representing a year-over-year increase of 15%[6]. - Revenue for 2024 is RMB 2,080.9 million, a decrease of 8.8% compared to RMB 2,282.2 million in 2023[18]. - Gross profit for 2024 is RMB 1,582.7 million, down 6.7% from RMB 1,695.7 million in 2023[18]. - Net profit for 2024 is RMB 175.4 million, an increase of approximately 9.6 times compared to RMB 16.6 million in 2023[18]. - Adjusted operating profit for 2024 is RMB 228.9 million, up 64.9% from RMB 138.8 million in 2023[18]. - The company's gross profit for 2024 was RMB 1,582.7 million, a decrease of 6.7% from RMB 1,695.7 million in 2023, with a gross margin of 76.1%[51]. - Operating profit for 2024 was RMB 192.0 million, significantly up from RMB 33.8 million in 2023, primarily due to improved efficiency in management, R&D, and sales teams[56]. - The company's revenue for the three months ended December 31, 2024, was RMB 563.6 million, a decrease of 10.6% compared to RMB 630.3 million for the same period in 2023[62]. - Revenue from providing talent acquisition and other human resources services to corporate clients was RMB 482.5 million, accounting for 85.6% of total revenue, down 11.9% from RMB 547.9 million in the previous year[63]. User Metrics - The number of registered individual users reached 2.5 million, an increase of 20% compared to the previous year[6]. - The total number of job postings on the platform increased by 35%, indicating a robust demand for recruitment services[6]. - The number of verified corporate users reached 1.43 million, while individual users surpassed 106 million by the end of 2024[23]. - Cumulative registered individual users reached 105.5 million, a year-on-year increase of 11.1%, with monthly active users growing by 5.6%[41]. - Annual paid individual users increased by 20.2% to 123,390 from 102,673 in 2023[32]. - The number of paid enterprise clients decreased by 5.7% to 67,913 from 72,037 in 2023[32]. Strategic Initiatives - The company plans to expand its market presence in Southeast Asia, targeting a 30% growth in user acquisition in the region over the next year[6]. - New product offerings in AI-driven recruitment solutions are expected to launch in Q3 2024, aiming to enhance user engagement by 25%[6]. - A strategic acquisition of a local competitor is anticipated to be completed by the end of Q2 2024, expected to increase market share by 10%[6]. - The company plans to continue enhancing its AI recruitment services and aims for a more agile approach to product innovation in 2025[25]. - The company is focusing on enhancing organizational efficiency and has upgraded its talent management system[34]. - The company aims to optimize recruitment processes through AI-driven insights and candidate matching[30]. Research and Development - The company has allocated HKD 200 million for research and development in 2024, focusing on innovative HR technologies[6]. - The company plans to upgrade its B-end enterprise version to an AI version by March 2025, focusing on AI applications in recruitment[44]. - The AI interview product, Doris, has achieved a scoring consistency of over 95% with senior expert evaluations[22]. - The AI intelligent interviewer "Doris" and the multi-recruitment consultant network (RCN) have gained market recognition, with plans to enhance talent profiling capabilities[45]. Operational Efficiency - The introduction of AI technology in recruitment processes has improved efficiency and reduced costs[35]. - The company aims to improve operational efficiency and talent delivery capabilities within the RCN network through continuous ecosystem development and AI digital assistant empowerment[45]. - The company aims to optimize operational efficiency and enhance product quality to meet diverse customer needs, focusing on personalized services and improving profitability[42]. Financial Management - Cash and cash equivalents as of December 31, 2024, were RMB 810.2 million, up from RMB 666.7 million as of December 31, 2023[79]. - Net cash generated from operating activities for 2024 was RMB 92.5 million, compared to RMB 18.3 million in 2023, primarily due to cost-saving measures and efficiency improvements[80]. - The company's debt-to-equity ratio as of December 31, 2024, was 1.27%, compared to 0.45% as of December 31, 2023[84]. - The company had short-term bank loans totaling RMB 58.0 million as of December 31, 2024, all secured with fixed interest rates ranging from 2.90% to 3.85%[86]. Shareholder Information - A special dividend of HKD 0.42 per share is declared, to be paid on May 8, 2025[18]. - The total comprehensive income attributable to owners of the company for 2024 was RMB 195.1 million, compared to RMB 36.9 million in 2023[78]. - The company has established credit policies to monitor credit risks associated with bank deposits, prepayments, and receivables[92]. - The company recognizes the importance of effective communication with shareholders to strengthen investor relations and ensure transparency in business performance[127]. Compliance and Governance - The company adheres to relevant laws and regulations, including the Companies Ordinance and the Corporate Governance Code, ensuring compliance in its operations[125]. - The company has implemented technology-based measures to protect personal information and comply with applicable privacy laws and regulations[132]. - The company’s independent non-executive directors confirmed their independence as of December 31, 2024, in accordance with the listing rules[145]. - The company has not established any arrangements allowing directors to benefit from purchasing shares or debt securities of the company[156]. Risks and Challenges - Major risks include the inability to improve user experience, adapt to user preferences, and respond to rapid product innovation demands, which could adversely affect business performance[129]. - The company faces various risks, including credit risk, liquidity risk, and currency risk, as detailed in the annual report's financial statements note 29[134]. - The company faces significant risks related to the contractual arrangements, including potential non-compliance with Chinese laws and regulations, which could lead to severe consequences[165]. Talent Management - The company has a performance-based compensation system for its sales team, which includes salary and performance bonuses based on total revenue generated and unique customer retention[195]. - The company's compensation policy is based on individual employee performance and is reviewed regularly[195]. - The remuneration for directors includes director's fees, salaries, housing allowances, and other benefits, with no payments made for joining or leaving the company[196].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 2025年度第一季度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.09(2)條及第13.10B 條以及香港法例第571章證券及期貨條例第XIVA項 下 的 內 幕 消 息 條 文 而 作 出。 下文為北京昭衍新藥研究中心股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱 「本集團」）於2025年財政年度的第一季度報告（「2025年度第一季度報告」）。本 公 告 及 隨 附 的 財 務 報 表 最 初 以 中 文 編 製，並 以 中 英 文 版 本 刊 登。如 中 英 文 版 本 出 現 任 何 歧 義 或 衝 ...

目錄 | 公司資料 | 2 | | --- | --- | | 主席報告 | 4 | | 董事及高級管理層的履歷 | 6 | | 管理層討論及分析 | 11 | | 董事會報告 | 16 | | 企業管治報告 | 30 | | 獨立核數師報告 | 48 | | 綜合損益及其他全面收益表 | 54 | | 綜合財務狀況表 | 55 | | 綜合權益變動表 | 57 | | 綜合現金流量表 | 58 | | 綜合財務報表附註 | 59 | | 財務概要 | 111 | 公司資料 董事會 執行董事 Tan Chee Beng先生 （主席兼行政總裁） Tang Ling Ling女士 Tan Wei Leong先生 張錦輝先生 顏建峰先生 獨立非執行董事 Wee Chorng Kien先生 梁又穩先生 梁基偉先生 審計委員會 梁又穩先生 （主席） Wee Chorng Kien先生 梁基偉先生 提名委員會 Tan Chee Beng先生 （主席） Wee Chorng Kien先生 梁基偉先生 薪酬委員會 梁又穩先生 （主席） Tan Chee Beng先生 Tang Ling Ling女士 Wee Chorng K ...